Small molecule
-
With global innovation map further expanded, Ascentage Pharma saw a 477% surge in revenue in the first half of 2024
The development of original new drugs has always been considered a high-risk industry. A d…
-
NASDAQ-listed companies are looking for obesity drugs with the potential for weight loss and muscle gain
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
-
Former Pfizer employees bravely venture into the red ocean of obesity drugs
Ambrosia, like Pfizer, is optimistic about the direction of oral small molecules, but whether it can surpass the front runners is something that still needs more time to verify
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
-
【Product for Licensing】Better Clinical Compound for Pulmonary IPF & PPF & ILD
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
-
【Product Wanted】HER2 Small Molecules That Can Penetrate BBB
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
-
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
Structure Therapeutics announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, along with positive topline results from its capsule to tablet PK study. Both studies achieved their primary and secondary objectives
